Regular coffee consumption (2-3 cups/day) protects against liver cirrhosis, reduces fibrosis, prevents liver cancer, and ...

Obeticholic acid is under clinical development by Intercept Pharmaceuticals and currently in Phase III for Biliary Atresia.

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosisalfapump® is ...

There’s no one-size-fits all number that applies to everyone. “But we know that even 7% to 10% of weight loss can have a ...

The global cirrhosis management market is projected to grow from US$ 725 million in 2023 to US$ 1,052.3 million by 2033, with ...

Lipocine Inc. (LPCN), a biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has granted Fast ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

Sarcopenia is a common complication of decompensated cirrhosis resulting in progressive loss of muscle mass and function. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

The following is a summary of “Evaluating the GALAD Score for Detection of Hepatocellular Carcinoma in Patients With ...

Trans- versus cisgender adults have an increased prevalence of cirrhosis but similar five-year survival, according to a study ...